ATE516308T1 - Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten - Google Patents

Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten

Info

Publication number: ATE516308T1
Authority: AT; Austria
Prior art keywords: helper; cell epitopes; lysine; internal; new immunogenic
Prior art date: 2002-08-12

Application number

AT03783851T

Other languages

English (en)

Inventor

David Jackson

Weiguang Zeng

Original Assignee

Queensland Inst Med Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-12

Filing date

2003-08-12

Publication date

2011-07-15

2003-08-12 Application filed by Queensland Inst Med Res filed Critical Queensland Inst Med Res

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE516308T1 publication Critical patent/ATE516308T1/de

Links

108010028921 Lipopeptides Proteins 0.000 title abstract 2
230000002163 immunogen Effects 0.000 title abstract 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
239000004472 Lysine Substances 0.000 abstract 2
210000003719 b-lymphocyte Anatomy 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
125000003473 lipid group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT03783851T 2002-08-12 2003-08-12 Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten ATE516308T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40283802P	2002-08-12	2002-08-12
PCT/AU2003/001018 WO2004014956A1 (en)	2002-08-12	2003-08-12	Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes

Publications (1)

Publication Number	Publication Date
ATE516308T1 true ATE516308T1 (de)	2011-07-15

Family

ID=31715903

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03783851T ATE516308T1 (de)	2002-08-12	2003-08-12	Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten

Country Status (12)

Country	Link
US (2)	US7569225B2 (de)
EP (2)	EP2301972A1 (de)
JP (2)	JP4619120B2 (de)
KR (1)	KR101240547B1 (de)
CN (3)	CN101121754B (de)
AT (1)	ATE516308T1 (de)
AU (1)	AU2003250586B2 (de)
BR (1)	BR0313154A (de)
CA (1)	CA2494192C (de)
DK (1)	DK1543039T3 (de)
ES (1)	ES2369664T3 (de)
WO (1)	WO2004014956A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7255867B2 (en) *	2002-11-15	2007-08-14	Id Biomedical Corporation Of Quebec	Vaccine
WO2006021048A1 (en) *	2004-08-26	2006-03-02	The Macfarlane Burnet Institute For Medical Research And Public Health Limited	Immunotherapy of virus infection
WO2006026834A1 (en)	2004-09-10	2006-03-16	The Council Of The Queensland Institute Of Medical Research (Qimr)	Truncated lhrh formulations
NZ556004A (en) *	2004-12-21	2010-05-28	Vaxinnate Corp	Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
US8420102B2 (en)	2006-03-07	2013-04-16	Vaxinnate Corporation	Compositions that include hemagglutinin
US20080233143A1 (en) *	2005-02-07	2008-09-25	Lipotek Pty Ltd.	Adjuvanting Material
CN101151280A (zh)	2005-02-08	2008-03-26	昆士兰医学研究学院委员会	免疫原性分子
CA2605321A1 (en)	2005-04-19	2006-10-26	Eli Lilly And Company	Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
AU2007284656A1 (en) *	2006-08-14	2008-02-21	Thymon, L.L.C.	Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
WO2008021296A2 (en) *	2006-08-14	2008-02-21	Thymon, L.L.C.	Compositions and methods for the treatment and prophylaxis of alzheimer's disease
BRPI0604997A (pt) *	2006-11-30	2007-05-22	Fundacao Zerbini	vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção
US9289485B2 (en)	2006-11-30	2016-03-22	Luiza Guilherme Guglielmi	Therapeutic application of S. pyogenes C-terminal peptide
AU2008310313C1 (en) *	2007-10-09	2015-02-12	Ena Respiratory Pty Ltd	A method of transfection and compositions therefor
US9138470B2 (en)	2007-11-02	2015-09-22	The Johns Hopkins University	Multi-component L2 vaccine for prevention of human papilloma virus infection
US8466259B2 (en) *	2007-12-07	2013-06-18	National Health Research Institutes	Adjuvants
WO2010003178A1 (en) *	2008-07-07	2010-01-14	The University Of Melbourne	A synthetic vaccine component
CN102256997A (zh)	2008-10-16	2011-11-23	美国辉瑞有限公司	细环病毒分离株和组合物
US8563690B2 (en) *	2008-11-03	2013-10-22	The Board Of Trustees Of The University Of Illinois	Modulation of platelet aggregation
CN103864895A (zh) *	2008-12-29	2014-06-18	隆萨布莱纳公司	制备比伐卢定的方法
JP2012523379A (ja)	2009-04-09	2012-10-04	ザユニバーシティーオブメルボルン	免疫原性組成物およびその使用
US8287880B2 (en)	2009-06-02	2012-10-16	National Health Research Institutes	Lipidated vaccine against dengue virus infection
EP2445927B1 (de) *	2009-06-22	2014-04-23	National Health Research Institutes	Lipidierte tumorassoziierte antigene und immuntherapiezusammensetzungen
DE102009034779A1 (de)	2009-07-25	2011-02-03	Emc Microcollections Gmbh	Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
US8846388B2 (en)	2009-10-16	2014-09-30	Zoetis Llc	Infectious clones of torque teno virus
EP2338521A1 (de)	2009-12-28	2011-06-29	Helmholtz-Zentrum für Infektionsforschung GmbH	Lipopeptid- und Lipoproteinkonjugate und ihre Verwendung
WO2011163593A2 (en) *	2010-06-25	2011-12-29	Philadelphia Health & Education Corporation D/B/A Drexel	Induction of immune response
US9295720B2 (en) *	2010-08-27	2016-03-29	Pantarhei Bioscience B.V.	Immunotherapeutic method for treating prostate cancer
EP2618842B1 (de)	2010-09-22	2019-04-24	Ena Therapeutics Pty Ltd	Neues immunstimulierendes verfahren
TW201221642A (en)	2010-11-15	2012-06-01	Nat Health Research Institutes	Method of producing lipidated polypeptides
TWI507413B (zh)	2010-11-15	2015-11-11	Nat Health Research Institutes	脂質化多抗原表位疫苗
DE102011018499A1 (de)	2011-04-23	2012-10-25	Emc Microcollections Gmbh	Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
WO2012162628A2 (en) *	2011-05-25	2012-11-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lipopeptide inhibitors of ras oncoproteins
EP2718429A1 (de)	2011-06-08	2014-04-16	Zoetis LLC	Infektiöse klone des torque-teno-virus
IN2014KN02769A (de) *	2012-06-06	2015-05-08	Bionor Immuno As
MX382968B (es) *	2012-11-16	2025-03-12	United Biomedical Inc	Vacuna de emergencia basada en péptidos sintéticos contra la fiebre aftosa.
EP3604271A1 (de)	2013-06-28	2020-02-05	Auckland Uniservices Limited	Peptide für aminosäure- und peptidkonjugate und konjugationsverfahren
WO2015157189A1 (en) *	2014-04-07	2015-10-15	The Regents Of The University Of California	Vaccines and uses thereof
CN107250103A (zh)	2014-12-23	2017-10-13	玛格丽特·安妮·布林布尔	氨基酸缀合物和肽缀合物以及其用途
GB201513921D0 (en) *	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017073797A1 (en) *	2015-10-28	2017-05-04	Ajinomoto Co., Inc.	Immunostimulating agent
TW201735952A (zh)	2016-02-26	2017-10-16	瑪格蕾特安布萊博	胺基酸及肽共軛物以及共軛過程
US11013798B2 (en)	2016-03-21	2021-05-25	South Dakota Board Of Regents	Orf virus-based platform for vaccine delivery
DE102016005550B4 (de)	2016-05-09	2024-09-26	Hans-Georg Rammensee	Adjuvans zur lnduzierung einer zellulären lmmunantwort
KR20190129032A (ko)	2016-12-28	2019-11-19	인벡스, 인크.	인플루엔자 백신
CN107703294B (zh) *	2017-10-12	2019-06-04	华派生物工程集团有限公司	一种用于检测鸡血清中cLHRH抗体效价的ELISA方法
AU2018391325B2 (en)	2017-12-21	2024-07-11	Axelia Oncology Pty Ltd	Optimised compounds
CN109991422A (zh) *	2017-12-29	2019-07-09	复旦大学	基于特异抗血清的棕榈酰化修饰蛋白质的检测方法
JP7550762B2 (ja) *	2018-12-20	2024-09-13	ヴァイロメティックスアーゲー	リポペプチドビルディングブロックおよび合成ウイルス様粒子
MX2021015961A (es)	2019-06-26	2022-03-22	Ena Respiratory Pty Ltd	Moleculas novedosas.
WO2021231767A1 (en)	2020-05-13	2021-11-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Rsv vaccine bearing one or more p gene mutations
CN114315985A (zh)	2020-09-29	2022-04-12	硕腾服务有限责任公司	减毒猪流行性腹泻病毒
TW202233647A (zh) *	2020-11-17	2022-09-01	挪威商霍夫賽思生物保健有限公司	呼吸治療
CN113009141A (zh) *	2021-02-05	2021-06-22	深圳市国赛生物技术有限公司	化学发光免疫检测试剂盒、用途和检测方法
CA3210091A1 (en) *	2021-02-05	2022-08-11	Amgen Inc.	Non-terminal antibody discovery methods and single cell assays
CN115216451A (zh)	2021-04-16	2022-10-21	硕腾服务有限责任公司	伪狂犬病病毒疫苗
CN118267462A (zh)	2022-12-29	2024-07-02	硕腾服务有限责任公司	接种猪以抗伪狂犬病病毒的方法
WO2024149888A1 (en) *	2023-01-12	2024-07-18	Isa Pharmaceuticals B.V.	Improved lipopeptide quantification
WO2025128971A1 (en)	2023-12-14	2025-06-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196265A (en)	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6024964A (en)	1985-06-24	2000-02-15	Hoechst Aktiengesellschaft	Membrane anchor/active compound conjugate, its preparation and its uses
US5864008A (en)	1988-03-25	1999-01-26	James; Stephen	Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
DE4119856A1 (de)	1991-06-17	1992-12-24	Hoechst Ag	N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
GB9202219D0 (en) *	1992-02-03	1992-03-18	Connaught Lab	A synthetic heamophilus influenzae conjugate vaccine
WO1993022343A1 (en)	1992-05-01	1993-11-11	The Rockfeller University	Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
AUPM885194A0 (en)	1994-10-14	1994-11-10	Council Of The Queensland Institute Of Medical Research, The	Synthetic peptides and vaccines comprising same
US5807978A (en)	1995-06-07	1998-09-15	Kokolus; William J.	Immunogenic peptides of prostate specific antigen
US6048538A (en)	1997-10-03	2000-04-11	United Biomedical, Inc.	Peptides derived from the non-structural proteins of foot and mouth disease virus as diagnostic reagents
US6107021A (en)	1998-06-20	2000-08-22	United Biomedical, Inc.	Synthetic peptide vaccines for foot-and-mouth disease
JP4699612B2 (ja)	1999-02-05	2011-06-15	ザユニバーシティオブメルボーン	Ｔヘルパー細胞エピトープ
WO2001070265A2 (en)	2000-03-24	2001-09-27	Biomira, Inc.	Lipopeptide adjuvants

2003
- 2003-08-12 AU AU2003250586A patent/AU2003250586B2/en not_active Ceased
- 2003-08-12 CN CN2007101287174A patent/CN101121754B/zh not_active Expired - Fee Related
- 2003-08-12 CN CNA038241498A patent/CN1688606A/zh active Granted
- 2003-08-12 US US10/525,301 patent/US7569225B2/en not_active Expired - Fee Related
- 2003-08-12 KR KR1020057002331A patent/KR101240547B1/ko not_active Expired - Fee Related
- 2003-08-12 CA CA2494192A patent/CA2494192C/en not_active Expired - Fee Related
- 2003-08-12 WO PCT/AU2003/001018 patent/WO2004014956A1/en not_active Ceased
- 2003-08-12 ES ES03783851T patent/ES2369664T3/es not_active Expired - Lifetime
- 2003-08-12 JP JP2004526517A patent/JP4619120B2/ja not_active Expired - Fee Related
- 2003-08-12 EP EP10011466A patent/EP2301972A1/de not_active Withdrawn
- 2003-08-12 AT AT03783851T patent/ATE516308T1/de active
- 2003-08-12 DK DK03783851.3T patent/DK1543039T3/da active
- 2003-08-12 EP EP03783851A patent/EP1543039B1/de not_active Expired - Lifetime
- 2003-08-12 BR BR0313154-8A patent/BR0313154A/pt not_active IP Right Cessation
- 2003-08-12 CN CN038241498A patent/CN1688606B/zh not_active Expired - Fee Related
2009
- 2009-06-19 US US12/488,485 patent/US8367067B2/en not_active Expired - Fee Related
- 2009-12-28 JP JP2009298035A patent/JP5265511B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1543039A1 (de)	2005-06-22
JP2010155832A (ja)	2010-07-15
WO2004014956A1 (en)	2004-02-19
AU2003250586B2 (en)	2010-09-23
AU2003250586A1 (en)	2004-02-25
CA2494192C (en)	2013-01-22
JP4619120B2 (ja)	2011-01-26
BR0313154A (pt)	2005-08-02
US8367067B2 (en)	2013-02-05
CN1688606B (zh)	2013-12-25
US20100092500A1 (en)	2010-04-15
JP2006513140A (ja)	2006-04-20
DK1543039T3 (da)	2011-10-31
US7569225B2 (en)	2009-08-04
CN101121754B (zh)	2012-02-29
EP1543039B1 (de)	2011-07-13
KR101240547B1 (ko)	2013-03-08
CN101121754A (zh)	2008-02-13
ES2369664T3 (es)	2011-12-02
US20070066534A1 (en)	2007-03-22
EP1543039A4 (de)	2007-09-19
HK1113163A1 (en)	2008-09-26
KR20050053608A (ko)	2005-06-08
EP2301972A1 (de)	2011-03-30
CA2494192A1 (en)	2004-02-19
JP5265511B2 (ja)	2013-08-14
CN1688606A (zh)	2005-10-26

Legal Events

Date

Code

Title

Description

2012-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1543039

Country of ref document: EP

Publication	Publication Date	Title
ATE516308T1 (de)	2011-07-15	Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten
ES2196305T3 (es)	2003-12-16	Composiciones que contienen moleculas inmunogenas y factor de estimulacion de colonias de granulocitos magrofagos como adyuvante.
PL366826A1 (en)	2005-02-07	Reducing the immunogenicity of fusion proteins
BRPI0208183B8 (pt)	2021-05-25	peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
DE69531204D1 (de)	2003-08-07	Formulierungen fuer faktor ix
BR0209434A (pt)	2006-02-07	Peptìdeos antimicrobianos e composições
BR9912176A (pt)	2002-11-05	Epìtopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de peptìdeo sintéticos incluindo peptìdeos de lhrh imunogênicos
DE69734605D1 (de)	2005-12-15	Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
AU6160201A (en)	2001-11-26	Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
ATE267211T1 (de)	2004-06-15	Impfstoff gegen hpv
BR9912177A (pt)	2001-04-10	Epìtopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptìdeo sintéticos
MXPA02006029A (es)	2004-08-23	Lipopeptidos novedosos como agentes antibacterianos.
CY1109230T1 (el)	2014-07-02	Ισομεραση συζευγμενου λινελαϊκου οξεος και μια διαδικασια για την παρασκευη συζευγμενου λινελαϊκου οξεος
AR002043A1 (es)	1998-01-07	Utilizacion de agonistas de alfa (1l) para el tratamiento de la incontinencia urinaria.
CY1114944T1 (el)	2016-12-14	Σταθεροποιημενα αλφα ελικοειδη πεπτιδια και χρησεις αυτων
MXPA02006030A (es)	2004-08-23	Lipopeptidos como agentes antibacterianos.
DK0506748T3 (da)	1996-01-22	Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
DE60015508D1 (de)	2004-12-09	C-16 ungesätigte fp-selektive prostaglandin analoge
ATE258933T1 (de)	2004-02-15	Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
GB9612214D0 (en)	1996-08-14	Vaccine
BR0316782A (pt)	2005-11-01	Produto de leite fermentado, processo para preparação de um produto de leite fermentado e uso da linhagem cnrz 244 de lactobacillus helveticus
EA200501204A1 (ru)	2006-06-30	Производные 3-(1-[3-(1,3-бензотиазол-6-ил)пропилкарбамоил]циклоалкил)пропановой кислоты в качестве ингибиторов нейтральной эндопептидазы (nep)
DE69530380D1 (de)	2003-05-22	Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
DK1420757T3 (da)	2006-07-10	Kosmetiske mikroemulsioner indeholdende ectoin eller derivater
AU2003267551A1 (en)	2004-03-11	Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone